Moberg Pharma
11.26 SEK
-2.34 %
Less than 1K followers
MOB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Moberg Pharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.2 | 9.8 | 13.5 | ||||
| growth-% | 38.0 % | ||||||
| EBITDA | - | -20.3 | -17.1 | -17.7 | -25.4 | -23.5 | -25.7 |
| EBIT | - | -22.8 | -19.7 | -20.2 | -27.5 | -324.8 | -27.3 |
| Profit before taxes | -22.8 | -20.0 | -19.5 | -25.4 | -320.5 | -24.0 | |
| Net income | - | -18.5 | -16.2 | -15.7 | -21.1 | -255.1 | -27.2 |
| EPS | 180.11 | -6.76 | -2.43 | -1.40 | -1.33 | -6.74 | -0.58 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | 0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -8,526.6 % | -239.7 % | -189.9 % | ||||
| EBIT-% | -9,772.9 % | -3,311.2 % | -201.8 % | ||||
| ROE | -4.7 % | -3.7 % | -2.9 % | -3.5 % | -37.1 % | -4.1 % | |
| ROI | -3.8 % | -3.6 % | -2.8 % | -3.3 % | -36.1 % | -4.0 % |